{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:31:21Z","timestamp":1793946681292,"version":"4.8.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,23]],"date-time":"2027-02-23T00:00:00Z","timestamp":1803340800000},"content-version":"am","delay-in-days":267,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["514898299"],"award-info":[{"award-number":["514898299"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["CA204484"],"award-info":[{"award-number":["CA204484"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["GM134954"],"award-info":[{"award-number":["GM134954"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["GM133114"],"award-info":[{"award-number":["GM133114"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cbpa.2026.102653","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T04:07:36Z","timestamp":1771819656000},"page":"102653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["DVD-IgG1 antibody\u2013drug conjugates: Expanding the landscape of targeted cancer therapy"],"prefix":"10.1016","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4540-6501","authenticated-orcid":false,"given":"Alexander F.","family":"Kiefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1252-1992","authenticated-orcid":false,"given":"Andrew D.","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9955-3454","authenticated-orcid":false,"given":"Christoph","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9750-5982","authenticated-orcid":false,"given":"Ben","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbpa.2026.102653_bib1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cbpa.2026.102653_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.cbpa.2026.102653_bib3","first-page":"157","article-title":"A review of conjugation technologies for antibody drug conjugates","volume":"8","author":"Fan","year":"2025","journal-title":"Antibiot Ther"},{"key":"10.1016\/j.cbpa.2026.102653_bib4","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1039\/D0CS00310G","article-title":"Site-selective modification strategies in antibody-drug conjugates","volume":"50","author":"Walsh","year":"2021","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.cbpa.2026.102653_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cbpa.2026.102653_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.cbpa.2026.102653_sref7","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nbt1345","article-title":"Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin","volume":"25","author":"Wu","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cbpa.2026.102653_bib8","unstructured":"C. Wu, T. Ghayur, R.W. Dixon and J.G. Salfeld, Dual variable domain immunoglobulin and uses thereof. US7612181B2, 2009."},{"key":"10.1016\/j.cbpa.2026.102653_bib9","series-title":"Dual variable domain immunoconjugates and uses thereof. US11197934B2","author":"Rader","year":"2021"},{"key":"10.1016\/j.cbpa.2026.102653_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-1-4939-9654-4_4","article-title":"Engineering dual variable domains for the generation of site-specific antibody-drug conjugates","volume":"2033","author":"Nanna","year":"2019","journal-title":"Methods Mol. Biol. (Clifton, N.J.)"},{"key":"10.1016\/j.cbpa.2026.102653_sref11","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.chembiol.2019.05.010","article-title":"Site-selective antibody functionalization via orthogonally reactive arginine and lysine residues","volume":"26","author":"Hwang","year":"2019","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.cbpa.2026.102653_sref12","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1021\/acs.jmedchem.2c01771","article-title":"Application of a biocatalytic strategy for the preparation of tiancimycin-based antibody-drug conjugates revealing key insights into structure-activity relationships","volume":"66","author":"Steele","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102653_sref13","first-page":"3171","article-title":"Second generation tiancimycin-based antibody-drug conjugates enabled by highly efficient semi-synthetic approach specifically targeting B-cell malignancies","volume":"5","author":"Kiefer","year":"2025","journal-title":"J. Am. Chem. Soc. Au"},{"key":"10.1016\/j.cbpa.2026.102653_bib14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1158\/1535-7163.MCT-17-0800","article-title":"ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting DLL4 and VEGF, demonstrates superior efficacy and favorable safety profiles in preclinical models","volume":"17","author":"Li","year":"2018","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.cbpa.2026.102653_sref15","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41587-022-01384-1","article-title":"Logic-gated antibody pairs that selectively act on cells co-expressing two antigens","volume":"40","author":"Oostindie","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cbpa.2026.102653_bib16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4161\/mabs.1.4.8755","article-title":"Molecular construction and optimization of anti-human IL-1alpha\/beta dual variable domain immunoglobulin (DVD-Ig) molecules","volume":"1","author":"Wu","year":"2009","journal-title":"mAbs"},{"key":"10.1016\/j.cbpa.2026.102653_bib17","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/19420862.2015.1026501","article-title":"Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1\u03b1 and IL-1\u03b2","volume":"7","author":"Lacy","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.cbpa.2026.102653_bib18","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.2217\/fon-2021-1603","article-title":"Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study","volume":"18","author":"Strickler","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.cbpa.2026.102653_bib19","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1126\/science.270.5243.1797","article-title":"Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes","volume":"270","author":"Wagner","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.cbpa.2026.102653_bib20","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1126\/science.278.5346.2085","article-title":"Immune versus natural selection: antibody aldolases with enzymic rates but broader scope","volume":"278","author":"Barbas","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.cbpa.2026.102653_bib21","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0022-2836(03)00992-6","article-title":"A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy","volume":"332","author":"Rader","year":"2003","journal-title":"J Mol Biol"},{"key":"10.1016\/j.cbpa.2026.102653_sref22","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41467-017-01257-1","article-title":"Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates","volume":"8","author":"Nanna","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.cbpa.2026.102653_bib23","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1021\/acs.bioconjchem.9b00609","article-title":"Site-specific lysine arylation as an alternative bioconjugation strategy for chemically programmed antibodies and antibody-drug conjugates","volume":"30","author":"Hwang","year":"2019","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.cbpa.2026.102653_bib24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tibtech.2014.02.003","article-title":"Chemically programmed antibodies","volume":"32","author":"Rader","year":"2014","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.cbpa.2026.102653_bib25","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1158\/1078-0432.CCR-10-2317","article-title":"Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth","volume":"17","author":"Huang","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cbpa.2026.102653_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080132","article-title":"Predictive markers of efficacy for an angiopoietin-2 targeting therapeutic in xenograft models","volume":"8","author":"Triana-Baltzer","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cbpa.2026.102653_bib27","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1021\/acs.bioconjchem.2c00146","article-title":"Sculpting a uniquely reactive cysteine residue for site-specific antibody conjugation","volume":"33","author":"Hwang","year":"2022","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.cbpa.2026.102653_bib28","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1021\/acs.biochem.0c00955","article-title":"An engineered arginine residue of unusual pH-sensitive reactivity facilitates site-selective antibody conjugation","volume":"60","author":"Nilchan","year":"2021","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbpa.2026.102653_bib29","doi-asserted-by":"crossref","first-page":"43424","DOI":"10.1021\/jacs.5c11236","article-title":"Chemical tagging of N-alkylamine-containing natural products and pharmaceuticals through C(sp3)-H functionalization","volume":"147","author":"Wang","year":"2025","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.cbpa.2026.102653_bib30","article-title":"A new immunochemical strategy for triple-negative breast cancer therapy","volume":"11","author":"Lin","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.cbpa.2026.102653_bib31","first-page":"71","article-title":"Dual-mechanistic antibody-drug conjugate via site-specific selenocysteine\/cysteine conjugation","volume":"2","author":"Nilchan","year":"2019","journal-title":"Antib. Ther."},{"key":"10.1016\/j.cbpa.2026.102653_bib32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nbt0798-677","article-title":"An efficient route to human bispecific IgG","volume":"16","author":"Merchant","year":"1998","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cbpa.2026.102653_bib33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1021\/acs.jnatprod.1c00065","article-title":"Natural product based antibody drug conjugates: clinical status as of November 9, 2020","volume":"84","author":"Newman","year":"2021","journal-title":"J Nat Prod"},{"key":"10.1016\/j.cbpa.2026.102653_bib34","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1021\/acs.jnatprod.5c00554","article-title":"The extraordinary benefit of Nature's chemistry to health, society, and the economy","volume":"88","author":"Moore","year":"2025","journal-title":"J Nat Prod"},{"key":"10.1016\/j.cbpa.2026.102653_bib35","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/cancers11030394","article-title":"Acquired resistance to antibody-drug conjugates","volume":"11","author":"Collins","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.cbpa.2026.102653_bib36","first-page":"1","article-title":"Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates","volume":"4","author":"Adhikari","year":"2021","journal-title":"Antib. Ther."},{"key":"10.1016\/j.cbpa.2026.102653_bib37","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107042118","article-title":"Uncialamycin-based antibody-drug conjugates: unique enediyne ADCs exhibiting bystander killing effect","volume":"118","author":"Nicolaou","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cbpa.2026.102653_bib38","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1021\/acs.jmedchem.3c02049","article-title":"DNA interaction and cleavage modes of anthraquinone-fused enediynes: a study on tiancimycins, yangpumicins, and their semisynthetic analogues","volume":"67","author":"Wen","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102653_bib39","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1021\/jacs.9b12522","article-title":"Total synthesis and biological evaluation of tiancimycins A and B, yangpumicin A, and related anthraquinone-fused enediyne antitumor antibiotics","volume":"142","author":"Nicolaou","year":"2020","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.cbpa.2026.102653_bib40","doi-asserted-by":"crossref","first-page":"8235","DOI":"10.1021\/jacs.6b04339","article-title":"Streamlined total synthesis of uncialamycin and its application to the synthesis of designed analogues for biological investigations","volume":"138","author":"Nicolaou","year":"2016","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.cbpa.2026.102653_bib41","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/s41589-024-01636-y","article-title":"Enediyne natural product biosynthesis unified by a diiodotetrayne intermediate","volume":"20","author":"Gui","year":"2024","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.cbpa.2026.102653_bib42","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1021\/acs.orglett.8b02584","article-title":"Comparative studies of the biosynthetic gene clusters for anthraquinone-fused enediynes shedding light into the tailoring steps of tiancimycin biosynthesis","volume":"20","author":"Yan","year":"2018","journal-title":"Org Lett"},{"key":"10.1016\/j.cbpa.2026.102653_bib43","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/bit.26944","article-title":"Streptomycin-induced ribosome engineering complemented with fermentation optimization for enhanced production of 10-membered enediynes tiancimycin-A and tiancimycin-D","volume":"116","author":"Zhuang","year":"2019","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.cbpa.2026.102653_bib44","doi-asserted-by":"crossref","first-page":"8432","DOI":"10.1021\/acs.jmedchem.0c00799","article-title":"Characterization of TnmH as an O-methyltransferase revealing insights into tiancimycin biosynthesis and enabling a biocatalytic strategy to prepare antibody-tiancimycin conjugates","volume":"63","author":"Adhikari","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102653_bib45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10295-018-2014-8","article-title":"Ribosome engineering and fermentation optimization leads to overproduction of tiancimycin A, a new enediyne natural product from Streptomyces sp. CB03234","volume":"45","author":"Liu","year":"2018","journal-title":"J Ind Microbiol Biotechnol"},{"key":"10.1016\/j.cbpa.2026.102653_sref46","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2498162","article-title":"Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations","volume":"17","author":"Wen","year":"2025","journal-title":"mAbs"}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593126000025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593126000025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:01:36Z","timestamp":1793944896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593126000025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":46,"alternative-id":["S1367593126000025"],"URL":"https:\/\/doi.org\/10.1016\/j.cbpa.2026.102653","relation":{},"ISSN":["1367-5931"],"issn-type":[{"value":"1367-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DVD-IgG1 antibody\u2013drug conjugates: Expanding the landscape of targeted cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbpa.2026.102653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102653"}}